However, because AAT is an acute phase reactant, it remains to be determine whether those without deficiency but perhaps a “suboptimal” level—which remains to be defined—may also benefit from AAT as a pharmacologic agent as has been suggested for cystic fibrosis patients (57). The gene discussed is SERPINA1; the disease is cystic fibrosis.